(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

The combination therapy showed a marked reduction in stress behaviors in animal models, indicating potential benefits for patients suffering from treatment-resistant depression. Eric Weisblum, CEO of ...

Silo Pharma has obtained exclusive rights to its spray mist technology for use with multiple indications, including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer's ...